Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults

Shots:

• The approval is based on P-III IMpower133 study results assessing Tecentriq + carboplatin and etoposide vs carboplatin and etoposide monothx in 403 adults with chemotherapy-naïve ES-SCLC
• P-III IMpower133 study results: mOS (12.3 mos. vs 10.3 mos.), mPFS (5.2 mos. vs 4.3 mos.) 30% reduction in death, OS @1 year (51.7% vs. 38.2%). The regimen is included as a preferred treatment for previously untreated ES-SCLC in the 2019 NCCN Clinical Practice Guidelines in Oncology for SCLC
• Tecentriq (atezolizumab) is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptor and novel therapy approved in Canada for SCLC and is being evaluated in 12 P-III trials as monothx or in combination with other drugs

Click here to read full press release/ article | Ref: Roche | Image: Behance